title: T lymphocyte activation in myasthenic thymoma.
abstract: The functional and phenotypic characteristics of lymphocytes separated from myasthenic thymoma (Th-L) were compared with those of lymphocytes separated from non-thymomatous thymus associated with thymoma (NTh-L) of the same patients and NTh-L of myasthenia gravis (MG) patients without thymoma. We examined whether Th-L and NTh-L of MG patients reacted to interleukin-2 (IL-2) to develop lymphokine-activated killer (LAK) activity and/or cytolytic activity against K562 (natural killer (NK) activity), and the phenotypic changes in such cells during incubation. Ten MG patients with thymoma and six MG patients without thymoma, and four non-MG thymoma patients were included in this study. Th-L and NTh-L of MG patients reacted with IL-2 to develop LAK and NK activities. The LAK activity developed from Th-L was significantly higher than that from NTh-L, and the LAK activity developed from Th-L was as high as that from peripheral blood lymphocytes (PBL) in MG patients without thymoma. The proportions of CD3+ cells, CD4+/CD8- cells, and CD4-/CD8+ cells in Th-L of MG patients increased significantly during incubation. On the other hand, the proportion of CD4+/CD8+ cells in Th-L of MG patients decreased significantly. The proportions of CD4+/CD8- cells, CD4-/CD8+ cells, and CD4+/CD8+ cells in NTh-L of MG patients with and without thymoma exhibited no change during incubation. These findings suggest that CD4+/CD8+ Th-L of MG patients may have a higher potential to react to IL-2 than NTh-L, and that the former cells might develop LAK activity like that of PBL on maturation to CD4+/CD8- cells and CD4-/CD8+ cells. Our findings also suggested that Th-L might play an important role in the pathogenesis of MG with thymoma.
authors.affiliation: The Second Department of Surgery, School of Medicine, The University of Tokushima, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Monden
mesh_terms: D000328:Adult; D000368:Aged; D016516:CD4-CD8 Ratio; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications / Q000276:immunology*; D010641:Phenotype; D011994:Recombinant Proteins / Q000494:pharmacology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D013945:Thymoma / Q000150:complications / Q000276:immunology*; D013953:Thymus Neoplasms / Q000150:complications / Q000276:immunology*
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins